Abstract
Today, we are experiencing a real cultural revolution in the therapeutic approach to cancer of the colon - rectum, that by orphan disease, it is now becoming an important paradigm of scientific innovations and concepts.
Survival of patients with metastatic colorectal cancer (m-CRC) has been significantly improved with the introduction of the monoclonal antibodies that have as target the vascular endothelial growth factor (VEGF) and the epidermal growth factor receptor (EGFR).
The PD-1/PD-L1 pathway in cancer is implicated in tumors escaping immune destruction. This pathway is up -regulated in many tumours. Blockade of this pathway with anti-PD-1 and anti-PD-L1 agents has led to remarkable clinical responses in patients affected by many different types of cancer.
The aim of this review is to evaluate the effects of addiction of biological agents to standard chemotherapy in the treatment of m-CRC.
We can say that, among the various treatment options, the challenge of the future will be a better selection of the population, to ensure the best possible benefit from treatment with anti-VEGF drugs or anti-EGFR and a careful and customized planning of the therapeutic strategy for each patient.
Keywords: Colorectal cancer, monoclonal antibodies, target therapy, treatment, anti-VEGF drugs, anti-EGFR.
Current Cancer Drug Targets
Title:Metastatic Colorectal Cancer: Role of Target Therapies and Future Perspectives
Volume: 18 Issue: 5
Author(s): Anna Nappi, Massimiliano Berretta, Carmela Romano, Salvatore Tafuto, Antonino Cassata, Rossana Casaretti, Lucrezia Silvestro, Chiara De Divitiis, Lara Alessandrini, Francesco Fiorica, Alessandro Ottaiano and Guglielmo Nasti*
Affiliation:
- Medical Oncology, Abdominal Department, National Cancer Institute G. Pascale Foundation, 80131 Napoli,Italy
Keywords: Colorectal cancer, monoclonal antibodies, target therapy, treatment, anti-VEGF drugs, anti-EGFR.
Abstract: Today, we are experiencing a real cultural revolution in the therapeutic approach to cancer of the colon - rectum, that by orphan disease, it is now becoming an important paradigm of scientific innovations and concepts.
Survival of patients with metastatic colorectal cancer (m-CRC) has been significantly improved with the introduction of the monoclonal antibodies that have as target the vascular endothelial growth factor (VEGF) and the epidermal growth factor receptor (EGFR).
The PD-1/PD-L1 pathway in cancer is implicated in tumors escaping immune destruction. This pathway is up -regulated in many tumours. Blockade of this pathway with anti-PD-1 and anti-PD-L1 agents has led to remarkable clinical responses in patients affected by many different types of cancer.
The aim of this review is to evaluate the effects of addiction of biological agents to standard chemotherapy in the treatment of m-CRC.
We can say that, among the various treatment options, the challenge of the future will be a better selection of the population, to ensure the best possible benefit from treatment with anti-VEGF drugs or anti-EGFR and a careful and customized planning of the therapeutic strategy for each patient.
Export Options
About this article
Cite this article as:
Nappi Anna, Berretta Massimiliano, Romano Carmela, Tafuto Salvatore, Cassata Antonino, Casaretti Rossana, Silvestro Lucrezia, Divitiis De Chiara, Alessandrini Lara, Fiorica Francesco, Ottaiano Alessandro and Nasti Guglielmo*, Metastatic Colorectal Cancer: Role of Target Therapies and Future Perspectives, Current Cancer Drug Targets 2018; 18 (5) . https://dx.doi.org/10.2174/1568009617666170209095143
DOI https://dx.doi.org/10.2174/1568009617666170209095143 |
Print ISSN 1568-0096 |
Publisher Name Bentham Science Publisher |
Online ISSN 1873-5576 |
Call for Papers in Thematic Issues
Advances in Cancer Biomarkers and Potential Drug Targets: From Diagnosis to Therapy
Cancer biomarkers play a crucial role in the diagnosis, prognosis, and treatment of cancer. They provide valuable information for cancer detection, risk assessment, treatment selection, and monitoring response to therapy. With advancements in molecular biology and high-throughput technologies, there has been an increasing interest in identifying and characterizing cancer biomarkers ...read more
Novel Therapeutic Approaches to Target Drug Resistant Tumors
With the development of disciplines such as chemical biology and molecular biology, the genes or proteins closely related to tumor occurrence and development have gradually become clear. Targeted therapies targeting these genes or proteins provide more effective methods for tumor treatment. Tumor targeted drugs generally only act on specific targets ...read more
ROLE OF IMMUNE AND GENOTOXIC RESPONSE BIOMARKERS IN TUMOR MICROENVIRONMENT IN CANCER DIAGNOSIS AND TREATMENT
Biological biomarkers have been used in medical research as an indicator of a normal or abnormal process inside the body, or of a disease. Nowadays, various researchers are in process to explore and investigate the biological markers for the early assessment of cancer. DNA Damage response (DDR) pathways and immune ...read more
Targeting the battlefield between host and tumor: basic research and clinical practice on reshaping tumor immune microenvironment
Immune system protects host against malignant tumors through effector cells and molecules. Cancer development and its response to therapy are regulated by inflammation, which either promotes or suppresses cancer progression. Chronic inflammation facilitates cancer progression and treatment resistance, whereas induction of acute inflammatory reactions often lead to anti-cancer immune responses. ...read more
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
Related Articles
-
Pharmacology of Topoisomerase I Inhibitors Irinotecan (CPT-11) and Topotecan
Current Cancer Drug Targets Strategies for Increasing the Solubility and Bioavailability of Anticancer Compounds: β-Lapachone and Other Naphthoquinones
Current Pharmaceutical Design Regulation of Mitochondrial Function and its Impact in Metabolic Stress
Current Medicinal Chemistry A Rationale for the Use of Proton Pump Inhibitors as Antineoplastic Agents
Current Pharmaceutical Design High-Risk HPV/ErbB-2 Interaction on E-Cadherin/Catenin Regulation in Human Carcinogenesis
Current Pharmaceutical Design Surface Markers of Cancer Stem Cells in Solid Tumors
Current Stem Cell Research & Therapy Virotherapy as An Approach Against Cancer Stem Cells
Current Gene Therapy Advances in the Researches on the Biological Activities and Inhibitors of Phosphatidylinositol 3-kinase
Anti-Cancer Agents in Medicinal Chemistry The Impact of Gynecological Cancer on Reproductive Issues and Pregnancy:Psychological Implications
Current Women`s Health Reviews Mechanism of Cancer Drug Resistance and the Involvement of Noncoding RNAs
Current Medicinal Chemistry Melatonin Regulates Angiogenic and Inflammatory Proteins in MDA-MB-231 Cell Line and in Co-culture with Cancer-associated Fibroblasts
Anti-Cancer Agents in Medicinal Chemistry Thymoquinone: Major Molecular Targets, Prominent Pharmacological Actions and Drug Delivery Concerns
Current Bioactive Compounds Phytochemical-Mediated Glioma Targeted Treatment: Drug Resistance and Novel Delivery Systems
Current Medicinal Chemistry N-Myristoyltransferase: A Novel Target
Mini-Reviews in Medicinal Chemistry Role of Monitoring Thiopurine Methyltransferase (TPMT) Activity in the Individualized Therapy with Azathioprine or 6-Mercaptopurine
Current Pharmacogenomics and Personalized Medicine Metabolic and Amino Acid Alterations of the Tumor Microenvironment
Current Medicinal Chemistry Regulation of Apoptosis by SYB in HepG2 Liver Cancer Cells is Mediated by the P53/Caspase 9 Axis
Anti-Cancer Agents in Medicinal Chemistry Farnesyltransferase Inhibitors: A Comprehensive Review Based on Quantitative Structural Analysis
Current Medicinal Chemistry Drosophila Neoplasias: Clues Towards the Understanding of Human Cancers
Current Genomics Patents on Immunotoxins and Chimeric Toxins for the Treatment of Cancer
Recent Patents on Drug Delivery & Formulation